Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Indo US Bio-Tech's Enterprise Value is ₹2,079 Mil.
Indo US Bio-Tech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹162 Mil. Therefore, Indo US Bio-Tech's EV-to-EBIT ratio for today is 12.86.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Indo US Bio-Tech's Enterprise Value is ₹2,079 Mil.
Indo US Bio-Tech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹171 Mil. Therefore, Indo US Bio-Tech's EV-to-EBITDA ratio for today is 12.18.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Indo US Bio-Tech's Enterprise Value is ₹2,079 Mil.
Indo US Bio-Tech's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,104 Mil. Therefore, Indo US Bio-Tech's EV-to-Revenue ratio for today is 1.88.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Indo US Bio-Tech (NSE:INDOUS) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Indo US Bio-Tech's current Enterprise Value is ₹2,079 Mil.
Indo US Bio-Tech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹162 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Indo US Bio-Tech's current Enterprise Value is ₹2,079 Mil.
Indo US Bio-Tech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹171 Mil.
Indo US Bio-Tech's current Enterprise Value is ₹2,079 Mil.
Indo US Bio-Tech's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,104 Mil.
Indo US Bio-Tech's current Enterprise Value is ₹2,079 Mil.
Indo US Bio-Tech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
Indo US Bio-Tech's current Enterprise Value is ₹2,079 Mil.
Indo US Bio-Tech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indo US Bio-Tech Enterprise Value Related Terms
Indo US Bio-Tech Enterprise Value Historical Data
* Premium members only.
The historical data trend for Indo US Bio-Tech's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INDOUS vs CTVA, CF, MOS: Enterprise Value Comparison
For the Agricultural Inputs subindustry, Indo US Bio-Tech's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indo US Bio-Tech Enterprise Value vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Indo US Bio-Tech's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Indo US Bio-Tech's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Indo US Bio-Tech's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indo US Bio-Tech (NSE:INDOUS) has a Enterprise Value of ₹2,079 Mil as of Jul. 04, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Indo US Bio-Tech and its competitors.
Is Indo US Bio-Tech's Enterprise Value too high?
Indo US Bio-Tech's current Enterprise Value is ₹2,079 Mil. Overall, Indo US Bio-Tech has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indo US Bio-Tech's Enterprise Value compare to CTVA and CF?
Indo US Bio-Tech's Enterprise Value of ₹2,079 Mil can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for an Agriculture company?
A good Enterprise Value depends on the Agriculture industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Indo US Bio-Tech and its competitors. Indo US Bio-Tech's current Enterprise Value is ₹2,079 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo US Bio-Tech stock overvalued right now?
Based on GuruFocus' analysis, Indo US Bio-Tech (NSE:INDOUS) is currently considered Possible Value Trap. The stock's GF Value™ is ₹292.74, compared to a current price of ₹89.15 — trading 69.5% below its estimated fair value. The current Enterprise Value is ₹2,079 Mil. Indo US Bio-Tech's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Indo US Bio-Tech (NSE:INDOUS), the current Enterprise Value is ₹2,079 Mil as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indo US Bio-Tech (NSE:INDOUS) Overvalued in 2026?
Based on GuruFocus' analysis, Indo US Bio-Tech stock appears to be undervalued.
The current stock price of ₹89.15 is trading 69.5% below its estimated GF Value™ of ₹292.74.
GuruFocus considers Indo US Bio-Tech to be Possible Value Trap.
Key valuation signals for NSE:INDOUS:
Enterprise Value: ₹2,079 Mil
GF Value™: ₹292.74 vs. price of ₹89.15 (69.5% below fair value)
No single metric tells the full story. See the NSE:INDOUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indo US Bio-Tech Ltd is a specialized agriculture seed company. It is involved in crop research and development through breeding, production of seeds, processing, packing, and marketing of high-performing hybrid and open-pollinated varieties of crops. The company's product portfolio includes a diversified variety of agricultural seeds, namely vegetable seeds, oil seeds, pulses seeds, cereals seeds, spices seeds used in cultivating all kinds of vegetables, pulses, crops like tomato, okra, brinjal, onion, bit root, cucumber, bottle gourd, groundnut, mustard, bajra, wheat, etc.
63GF Score
Get the complete analysis for NSE:INDOUS
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDOUS has been successfully added to your 
